Paper Details

  1. Home
  2. Paper Details

Short-term prednisolone followed by recombinant human alpha-interferon alone or combined with adenine-arabinoside in chronic hepatitis B. A prospective and randomized trial.

Author: BlayauM, BrissotP, DavidV, DeugnierY, GuyaderD, GuéguenM, JacquelinetC, JouanolleH, LescoatG, MessnerM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared two treatment regimens for chronic hepatitis B: a course of prednisolone followed by interferon (group 1) and prednisolone followed by a combination of adenine-arabinoside and interferon (group 2). Both treatments were well-tolerated, with significant side effects leading to early discontinuation of interferon occurring in only four patients in group 2. Both groups showed similar improvements in liver function, with 59% of patients experiencing a sustained decrease in hepatitis B virus levels and a significant reduction in liver enzymes. These findings suggest that interferon, alone or in combination with adenine-arabinoside, may be a beneficial treatment for chronic hepatitis B.
Paper Details　
Original Abstract of the Article :
Twenty-nine patients with chronic hepatitis B, presenting both hepatitis B surface antigen and hepatitis B virus deoxyribonucleic acid in serum, were studied in a randomized trial treatment consisting of oral prednisolone for 28 days followed 14 days after steroid withdrawal, by either a 55 s.c. inj...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0168-8278(91)90936-6

データ提供：米国国立医学図書館（NLM）

Short-Term Prednisolone Followed by Interferon Therapy for Chronic Hepatitis B

This research delves into the field of virology and hepatology, exploring the effectiveness of a combination therapy involving prednisolone and interferon for the treatment of chronic hepatitis B (CHB). The study involved a randomized trial of 29 patients with CHB, comparing the efficacy of two treatment regimens: a short course of prednisolone followed by recombinant human alpha-interferon alone, and the same regimen combined with adenine-arabinoside. The authors aimed to evaluate the long-term effects of these therapies on viral load, liver function, and overall patient outcomes.

Promising Results for Chronic Hepatitis B Treatment

The results of this randomized trial demonstrated a significant positive impact of both treatment regimens on CHB. A substantial proportion of patients (59%) exhibited a sustained disappearance of hepatitis B virus deoxyribonucleic acid (DNA) in their serum, indicating a successful suppression of viral replication. This was accompanied by marked improvement in liver function, as evidenced by a quasi-normalization of serum transaminase levels. These findings suggest that a combination therapy involving prednisolone and interferon holds significant promise as a treatment option for CHB, offering hope for improved patient outcomes and potentially leading to long-term remission.

The Importance of Effective Treatment for Hepatitis B

For individuals living with CHB, this research offers a beacon of hope, highlighting the potential of combination therapy to control viral replication and improve liver function. Imagine a desert oasis under threat from a relentless sandstorm. Effective treatment for CHB would be like a sturdy dam, protecting the oasis from the destructive force of the virus, allowing it to flourish and thrive. Early detection and timely treatment are crucial for minimizing the long-term complications of CHB and preserving liver health.

Dr. Camel's Conclusion

This research showcases the power of collaboration and innovation in the fight against chronic diseases. Just as a caravan of travelers working together can overcome the challenges of a harsh desert journey, researchers pooling their expertise and utilizing a combination of therapies have achieved significant progress in managing CHB. The results offer a glimmer of hope for patients and a roadmap for future research, reminding us that even in the face of adversity, progress is possible.

Date :
  1. Date Completed 1991-07-19
  2. Date Revised 2019-08-17
Further Info :

Pubmed ID

2050997

DOI: Digital Object Identifier

10.1016/0168-8278(91)90936-6

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.